Company to feature its recently launched
Beacon Select™ technology for antibody discovery and cell line
development
EMERYVILLE, Calif.,
June 5, 2023 /PRNewswire/ -- PhenomeX
Inc. (Nasdaq: CELL), the functional cell biology company, today
announced its participation in the Antibody Engineering &
Therapeutics (AE&T) Europe
2023 from 6-8 June 2023 at the
Postillion Hotel Amsterdam. AE&T is the leading antibody
meeting in Europe bringing
together world-renowned scientists and academic researchers to
deliver the latest science, technologies and partners needed to
help scientists accelerate next generation antibodies towards
commercial success.
At the conference, the Company will feature its optofluidic and
proteomic technologies, including its recently launched Beacon
Select™ technology, in booth #19 and attendees can explore
demonstrations and learn more about how PhenomeX's products can
advance and accelerate our understanding of cellular function along
the continuum of scientific discovery, bioprocessing, clinical
research, and immunotherapy development.
In addition, PhenomeX's technology will be highlighted in a
podium presentation led by Dr. Francois Romagne, chief scientific
officer of MImAbs and professor at Aix Marseille University.
Presentation title: "Accelerating Antibody Discovery for
Difficult Targets through mRNA Immunization and Beacon Single Cell
Technology"
Date & time: Wednesday, 7 June
2023 at 12:20 p.m. CET
Abstract: This presentation will show that despite demonstrating
efficiency in antibody generation, classical immunization
strategies and subsequent hybridoma generation often face strong
limitations when it comes to poorly immunogenic membrane proteins
with short extracellular domains. Indeed, even if a few antibodies
can be obtained with repeated campaigns, only limited diversity and
molecular characteristics are achieved, resulting in difficulties
in selecting good candidates for pharmaceutical developments.
Innovative approaches combining RNA immunization and single cell
screening provide unique opportunities to dramatically speed up
antibody discovery against such challenging targets. In the
presentation, obtention of large collections of antibodies with
both molecular and function diversity against a difficult GPCR and
ion channel will be described using these strategies.
About PhenomeX Inc.
PhenomeX is empowering scientists to leverage the full potential
of each cell and drive the next era of functional
cell biology that will advance human health. We enable
scientists to reveal the most complete insights on cell function
and obtain a full view of the behavior of each cell. Our unique
suite of proven high-throughput tools and services offer
unparalleled resolution and speed, accelerating the insights that
are key to advancing discoveries that can profoundly improve the
prevention and treatment of disease. Our award-winning
platforms are used by researchers across the globe, including those
at the top 15 global pharmaceutical companies and approximately 85%
of leading U.S. comprehensive cancer centers.
Forward-Looking Statements
To the extent that
statements contained in this press release are not descriptions of
historical facts regarding PhenomeX or its products, they are
forward-looking statements reflecting the current beliefs and
expectations of management. Such forward-looking statements involve
substantial known and unknown risks and uncertainties that relate
to future events, and actual results and product performance could
differ significantly from those expressed or implied by the
forward-looking statements. PhenomeX undertakes no obligation to
update or revise any forward-looking statements. For a further
description of the risks and uncertainties relating to the
Company's growth and continual evolution see the statements in the
"Risk Factors" sections, and elsewhere, in our filings with the
U.S. Securities and Exchange Commission.
View original
content:https://www.prnewswire.co.uk/news-releases/phenomex-to-participate-in-antibody-engineering--therapeutics-europe-2023-301841892.html